CompletedPhase 3
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Key facts
- Who runs it
- Sun Pharmaceutical Industries, Inc.
- Where
- France, Germany, Hungary, Poland, and Spain39 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 407 people enrolled
- Started
- 19 Oct 2021
- Ended
- 18 Jul 2024
- Type of study
- Interventional
- Treatments tested
- CTP-543
- Record updated
- 21 November 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Who cannot take part
- Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of study medication
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
The group in the trial
- CTP-543Treatment being tested
Patients who previously completed a qualifying CTP-543 clinical trial
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- Publications
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.Journal of the American Academy of Dermatology, 2026
- Record updated
- 21 November 2025